Recent Company News

• 07:04 AM ET Aug 27, 2025
  

  Merck announces first patient has been dosed in the HERTHENA-Breast04 phase 3 trial ($84.99, 0.00)

• 03:09 AM ET Aug 25, 2025
  

  Daiichi Sankyo's ENHERTU obtains Japan MHLW approval as first HER2 direct medicine for treatment of breast cancer (¥3716.0000, 0)

• 11:32 AM ET Aug 22, 2025
  

  StreetAccount Activist Summary: Week of 18-Aug

• 08:36 AM ET Aug 22, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:57 AM ET Aug 22, 2025
  

  Daiichi Sankyo (4568.JP) and AstraZeneca announce China NMPA approval of Dazhuoyou (Datroway) in HR-positive, HER2-negative metastatic breast cancer (12052.0000p, +4)

• 05:01 AM ET Aug 21, 2025
  

  Three financial institutions offered to sell up to ¥188B combined of Daiichi Sankyo shares at maximum 7% discount on yesterday's closing price - Bloomberg (¥3710.0000, 0)

• 11:35 PM ET Aug 20, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:49 PM ET Aug 18, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:08 AM ET Aug 18, 2025
  

  Daiichi Sankyo's ifinatamab deruxtecan granted Breakthrough Therapy Designation by US FDA for treatment of adult patients with extensive-stage small cell lung cancer (¥3782.0000, 0)